Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm.

Additional information about the conference may be found at www.sachsforum.com. Attendees who wish to meet with management one on one may contact our Investor Relations department investors@tmedpharma.com

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. (OTCQB: TRGM) is a publicly traded, Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes amino acid based medical foods, a rapidly growing sector of medication technology, for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders using the patented system of Targeted Cellular Technology.

The company also develops a line of dietary supplements designed to support health and wellness.  TMP currently manufactures 10 proprietary amino acid based medical foods, and recently launched its first dietary supplement, Clearwayz™.  The products are sold directly to physicians and pharmacies in the U.S. The Company is also developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Follow the Company on twitter @tmedpharma

####